FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily.
Danish: Behandling af DVT, behandling af LE og forebyggelse af recidiverende DVT og LE (VTEt) Den anbefalede dosis af apixaban til behandling af akut DVT og behandling af LE er 10 mg oralt to gange dagligt de første 7 dage efterfulgt af 5 mg oralt to gange dagligt.
English: Both studies were randomised, parallel-group, double-blind, multinational trials in patients with symptomatic proximal DVT or symptomatic PE. All the key safety and efficacy endpoints were adjudicated by an independent blinded committee.
Danish: Begge studier var randomiserede, parallel-gruppe, dobbeltblinde, multinationale forsøg med patienter med symptomatisk proksimal DVT eller symptomatisk LE.
English: In a study comparing 8 subjects with mild hepatic impairment, Child-Pugh A score 5 (n = 6) and score 6 (n = 2), and 8 subjects with moderate hepatic impairment, Child-Pugh B score 7 (n = 6) and score 8 (n = 2), to 16 healthy control subjects, the single-dose pharmacokinetics and pharmacodynamics of apixaban 5 mg were not altered in subjects with hepatic impairment.
Danish: I et forsøg, hvor 8 patienter med let nedsat leverfunktion (Child Pugh A score 5 (n = 6) og score 6 (n = 2)), og 8 patienter med moderat nedsat leverfunktion (Child Pugh B score 7 (n = 6) og score 8 (n = 2)), blev sammenlignet med 16 raske forsøgspersoner, blev der ikke set nogen ændring i farmakokinetik og farmakodynamik ved engangsdosering af apixaban 5 mg hos patienter med nedsat leverfunktion.
English: - a severe kidney disease or if you are on dialysis - a liver problem or a history of liver problems Eliquis will be used with caution in patients with signs of altered liver function.
Danish: - hvis De har en alvorlig nyresygdom eller hvis De er i dialyse - hvis De har en leversygdom eller tidligere har haft en leversygdom Eliquis vil blive anvendt med forsigtighed til patienter med tegn på ændringer i leverfunktionen.
English: - Changing from Eliquis to anticoagulant treatment containing vitamin K antagonist (e.g., warfarin).
Danish: - Skift fra Eliquis til behandling med blodfortyndende medicin, der indeholder vitamin K-antagonist (f.eks. warfarin).
English: In patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp the following recommendations apply (see section 4.5):
Danish: Hos patienter, der får samtidig systemisk behandling med potente induktorer af både CYP3A4 og P-gp, gælder følgende anbefalinger (se pkt.
English: Changes in anti-Factor Xa activity and INR were comparable between subjects with mild to moderate hepatic impairment and healthy subjects.
Danish: Ændringer i anti-faktor Xa-aktivitet og INR var sammenlignelige mellem gruppen af patienter med mild til moderat nedsat leverfunktion og gruppen af raske forsøgspersoner.
English: Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery.
Danish: Selv om behandling med apixaban ikke kræver rutinemæssig kontrol af eksponeringen, kan en kalibreret kvantitativ test for anti‑faktor Xa være nyttig i særlige situationer, hvor kendskabet til eksponeringen til apixaban kan være en hjælp til at tage kliniske beslutninger, f.eks. ved overdosering og akut kirurgi.
English: It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B).
Danish: Eliquis kan anvendes med forsigtighed til patienter med let til moderat nedsat leverfunktion (Child Pugh A eller B).
English: Coadministration of apixaban (20 mg once a day) and digoxin (0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or Cmax.
Danish: Samtidig indgivelse af apixaban (20 mg 1 gang dagligt) og digoxin (0,25 mg 1 gang dagligt), et P-gp substrat, påvirkede ikke digoxins AUC eller Cmax.
English: Pink, oval tablets debossed with 894 on one side and 5 on the other side.
Danish: Pink, ovale tabletter præget med 894 på den ene side og 5 på den anden side.
English: The film-coated tablets are yellow, round and marked with “893” on one side and “2½” on the other side.
Danish: De filmovertrukne tabletter er gule, runde og mærket med ”893” på den ene side og ”2½” på den anden side.
English: Table 4: Efficacy Results from Pivotal Phase III Studies Study
Danish: Tabel 4: Effektparametre i pivotale fase III‑forsøg Forsøg
English: Your doctor needs to do blood-measurements and instruct you when to stop taking Eliquis.
Danish: Lægen vil tage blodprøver og fortælle Dem, hvornår De skal stoppe med at tage Eliquis.
English: Interaction with other medicinal products affecting haemostasis Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).
Danish: Interaktion med andre lægemidler, der påvirker hæmostasen På grund af forhøjet blødningsrisiko er samtidig behandling med andre antikoagulantia kontraindiceret (se pkt.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 2.5 mg
Danish: MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE KARTON 2,5 mg
English: There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 7).
Danish: Der var ingen statistisk signifikant forskel i incidensen af major blødning mellem apixaban og ASA (se Tabel 7).
English: A stroke can be life-threatening and requires immediate medical attention.
Danish: Et slagtilfælde kan være livsfarligt og kræver øjeblikkelig lægehjælp.
English: INFORMATION IN BRAILLE Eliquis 2.5 mg
Danish: INFORMATION I BRAILLESKRIFT Eliquis 2,5 mg
English: Anticoagulants, platelet aggregation inhibitors, SSRIs/SNRIs and NSAIDs Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated except under specific circumstances of switching anticoagulant therapy, when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation (see section 4.3).
Danish: Antikoagulantia, trombocytaggregationshæmmere, SSRI'er/SNRI'er og NSAID På grund af øget blødningsrisiko er samtidig behandling med andre antikoagulantia kontraindiceret, undtagen i særlige tilfælde i forbindelse med skift af antikoagulationsbehandling, når UFH administreres i doser, der er nødvendige for at opretholde et åbent centralt vene- eller arteriekateter, eller når UFH administreres under kateterablation for atrieflimren (se pkt.
English: Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel 75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of platelet aggregation, compared to administration of the antiplatelet agents without apixaban.
Danish: Ved samtidig behandling med apixaban og clopidogrel (75 mg 1 gang dagligt), kombinationen af clopidogrel 75 mg og ASA 162 mg 1 gang dagligt eller med prasugrel (60 mg efterfulgt af 10 mg en gang dagligt), blev der i et fase I studie ikke set relevant forlængelse af standardiseret blødningstid eller yderligere hæmning af trombocytaggregation sammenlignet med administration af thrombocythæmmere uden apixaban.
English: In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR≥ 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.
Danish: I AMPLIFY-studiet blev ialt 5.395 patienter randomiseret til behandling med apixaban 10 mg oralt to gange dagligt i 7 dage efterfulgt af apixaban 5 mg oralt to gange dagligt i 6 måneder eller til enoxaparin 1 mg/kg subkutant to gange dagligt i mindst 5 dage (indtil INR≥ 2) og warfarin (målinterval for INR 2,0-3,0) oralt i 6 måneder.
English: In the knee replacement surgery study during the intended treatment period, in the apixaban arm 4 cases of PE were diagnosed against no cases in the enoxaparin arm. No explanation can be given to this higher number of PE.
Danish: I knæalloplastik studiet blev der i løbet af den tilsigtede behandlingsperiode observeret 4 tilfælde af lungeembolier (LE) i apixabangruppen og ingen tilfælde i enoxaparingruppen.
English: The safety of apixaban has been investigated in 7 Phase III clinical studies including more than 21,000 patients: more than 5,000 patients in VTEp studies, more than 11,000 patients in NVAF studies and more than 4,000 patients in the VTE treatment (VTEt) studies, for an average total exposure of 20 days, 1.7 years and 221 days respectively (see section 5.1).
Danish: Sikkerheden ved apixaban er undersøgt i 7 kliniske fase-III-studier med flere end 21.000 patienter: flere end 5.000 patienter i VTEp‑studierne, flere end 11.000 patienter i NVAF‑studierne og flere end 4.000 patienter i VTE‑behandlingsstudierne (VTEt) med en gennemsnitlig total eksponering på henholdsvis 20 dage, 1,7 år og 221 dage (se pkt.
English: In the AMPLIFY-EXT study a total of 2,482 patients were randomised to treatment with apixaban 2.5 mg twice daily orally, apixaban 5 mg twice daily orally, or placebo for 12 months after completing 6 to 12 months of initial anticoagulant treatment.
Danish: I AMPLIFY‑EXT‑studiet blev i alt 2.482 patienter randomiseret til behandling med apixaban 2,5 mg oralt to gange dagligt, apixaban 5 mg oralt to gange dagligt eller placebo i 12 måneder efter at have afsluttet 6 til 12 måneders initial antikoagulationsbehandling.
English: Eliquis should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established (for cardioversion see section 4.2).
Danish: Behandling med Eliquis bør genoptages så hurtigt som muligt efter det invasive indgreb eller kirurgiske indgreb, forudsat at den kliniske situation tillader det og ædakvat hæmostase er opnået (se pkt.
English: Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) The clinical program (AMPLIFY: apixaban versus enoxaparin/warfarin, AMPLIFY-EXT: apixaban versus placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY), and extended therapy for the prevention of recurrent DVT and/or PE following 6 to 12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT).
Danish: Behandling af DVT, behandling af LE og forebyggelse af recidiverende DVT og LE (VTEt) Det kliniske program (AMPLIFY: apixaban versus enoxaparin/warfarin, AMPLIFY-EXT: apixaban versus placebo) var designet til at påvise apixabans virkning og sikkerhed ved behandling af DVT og/eller LE (AMPLIFY), og ved langvarig behandling til forebyggelse af recidiverende DVT og/eller LE efter 6 til 12 måneders antikoagulationsbehandling ved DVT og/eller LE (AMPLIFY-EXT).
English: There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 9).
Danish: Der var ingen statistisk signifikant forskel i incidensen af major blødning mellem apixaban og ASA (se Tabel 9).
English: Study treatment Dose
Danish: Behandling Dosis
English: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).
Danish: Forebyggelse af apopleksi og systemisk emboli hos voksne patienter med non-valvulær atrieflimren (NVAF) med en eller flere risikofaktorer, såsom apopleksi eller transitorisk iskæmisk attak (TIA) i anamnesen, alder ≥ 75 år, hypertension, diabetes mellitus, symptomatisk hjertesvigt (NYHA-klasse ≥ II).
English: Major Major + CRNM Minor All
Danish: Major Major + CRNM Minor Alle
English: Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of D5W and delivered via a nasogastric tube, exposure was similar to exposure seen in other clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose.
Danish: Efter administration af en knust 5 mg apixaban tablet opløst i 60 ml 5% glucose i vand og indgivet via nasogastrisk sonde var eksponeringen sammenlignelig med eksponeringen observeret i andre kliniske forsøg med raske forsøgspersoner, der fik en 5 mg apixaban‑tablet som oral enkeltdosis.
English: Stroke or systemic embolism 212 (1.27) 265 (1.60) 0.79 (0.66, 0.95) 0.0114 Stroke Ischaemic or unspecified 162 (0.97) 175 (1.05) 0.92 (0.74, 1.13) Haemorrhagic Systemic embolism 15 (0.09) 17 (0.10) 0.87 (0.44, 1.75)
Danish: Apopleksi eller systemisk emboli 212 (1,27) 265 (1,60) 0,79 (0,66; 0,95) 0,0114 Apopleksi Iskæmisk eller uspecificeret 162 (0,97) 175 (1,05) 0,92 (0,74; 1,13) Hæmoragisk Systemisk emboli
English: Anhydrous lactose Microcrystalline cellulose (E460) Croscarmellose sodium Sodium laurilsulfate Magnesium stearate (E470b)
Danish: Mikrokrystalinsk cellulose (E460) Croscarmellosenatrium Natriumlaurylsulfat Magnesiumstearat (E470b)
English: Intra-abdominal haemorrhage
Danish: Intra-abdominal blødning
English: For patients randomised to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%.
Danish: Hos patienter randomiseret til warfarin var gennemsnitstid i terapeutisk interval (TTI) (INR 2-3) 66%.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER 2.5 mg (Symbol)
Danish: MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP BLISTER 2,5 mg (symbol)
English: The administration of apixaban 10 mg with famotidine 40 mg had no effect on apixaban AUC or Cmax.
Danish: Administration af apixaban 10 mg og famotidin 40 mg havde ingen effekt på AUC og Cmax for apixaban.
English: In studies conducted in healthy subjects, as described below, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, or atenolol.
Danish: I nedenstående forsøg med raske forsøgspersoner sås ingen betydelig ændring i farmakokinetikken af digoxin, naproxen eller atenolol.
English: In this clinical trial, there was limited (2.1%) use of concomitant dual antiplatelet therapy.
Danish: I dette kliniske forsøg var brugen af samtidig behandling med to trombocythæmmende midler begrænset (2,1%).
English: Hepatobiliary disorders Liver function test abnormal, asparate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased
Danish: Abnorme leverfunktionsprøver, forhøjet aspartataminotransferase, stigning i basisk phosphatase, forhøjet bilirubin i blodet
English: Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (e.g., diltiazem, naproxen, clarithromycin, amiodarone, verapamil, quinidine) are expected to increase apixaban plasma concentration to a lesser extent.
Danish: Aktive stoffer, der ikke anses for at være stærke hæmmere af både CYP3A4 og P-gp (f.eks. diltiazem, naproxen, clarithromycin, amiodaron, verapamil, quinidin) forventes i mindre grad at øge plasmakoncentrationen af apixaban.
English: No dose adjustment for apixaban is required when coadministered with agents that are not strong inhibitors of both CYP3A4 and P-gp.
Danish: Dosisjustering for apixaban er ikke nødvendig ved samtidig behandling med stoffer, der ikke er potente hæmmere af både CYP3A4 og P-gp.
English: In the AVERROES study a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomised to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%], see section 4.2) or ASA.
Danish: I AVERROES studiet blev i alt 5.598 patienter, som af investigatorerne blev bedømt som uegnede til VKA, randomiseret til behandling med apixaban 5 mg to gange dagligt (eller 2,5 mg to gange dagligt hos udvalgte patienter [6,4%], se pkt.
English: The following medicines may reduce the ability of Eliquis to help prevent blood clots from forming: - medicines to prevent epilepsy or seizures (e.g., phenytoin, etc.) - St John's Wort (a herbal supplement used for depression) - medicines to treat tuberculosis or other infections (e.g., rifampicin)
Danish: Følgende lægemidler kan nedsætte virkningen af Eliquis til at forebygge blodpropper: - medicin til forebyggelse af epilepsi eller kramper (f.eks. fenytoin etc.) - perikum (et naturlægemiddel som bruges mod depression) - medicin til behandling af tuberkulose eller andre infektioner (f.eks. rifampicin)
English: Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see section 5.1).
Danish: Selvom behandling med apixaban ikke kræver rutinemæssig overvågning af eksponeringen, kan en kalibreret kvantitativ test for anti‑faktor Xa være nyttig i exceptionelle situationer, hvor viden om apixaban-eksponering kan være en hjælp til at tage kliniske beslutninger, f.eks.ved overdosering og akut kirurgi (se pkt.
English: A total of 8,464 patients were randomised in two pivotal, double-blind, multi-national studies, comparing apixaban 2.5 mg given orally twice daily (4,236 patients) or enoxaparin 40 mg once daily (4,228 patients).
Danish: I alt 8.464 patienter blev randomiseret til 2 pivotale, dobbeltblindede, multinationale forsøg, hvor apixaban 2,5 mg indgivet oralt 2 gange dagligt (4.236 patienter) blev sammenlignet med enoxaparin 40 mg 1 gang dagligt (4.228 patienter).
English: - Bleeding: - into a muscle - in your eyes - from your gums and blood in your spit when coughing - from your rectum - Hair loss
Danish: - Blødning: - i en muskel - i øjnene - fra gummerne og blod i spyttet i forbindelse med hoste - fra endetarmen - Hårtab
English: Therefore, the use of Eliquis is not recommended in this setting.
Danish: Eliquis frarådes derfor i disse tilfælde.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Danish: De kan finde yderligere oplysninger om Eliquis på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu/.
English: Patients undergoing catheter ablation (NVAF) Patients can continue apixaban use while undergoing catheter ablation (see sections 4.3, 4.4 and 4.5).
Danish: Patienter, der får foretaget kateterablation (NVAF) Patienterne kan fortsætte med at bruge apixaban, mens de får foretaget kateterablation (se pkt.
English: Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability.
Danish: Ændringerne i koagulationstests ved en given terapeutisk dosis er små og har en høj grad af variabilitet.
English: - you have severely reduced kidney function - two or more of the following apply to you: - your blood test results suggest poor kidney function (value of serum creatinine is 1.5 mg/dL (133 micromole/L) or greater) - you are 80 years old or older - your weight is 60 kg or lower.
Danish: - De har svært nedsat nyrefunktion - to eller flere af følgende punkter gælder for Dem: - Deres blodprøver tyder på, at De har nedsat nyrefunktion (Deres serumkreatinin-tal er 1,5 mg/dl (133 mikromol/l) eller mere) - De er 80 år eller derover - De vejer 60 kg eller under.
English: Warfarin N=9,081 n (%/yr)
Danish: Warfarin N=9.081 n (%/år)
English: - for the prevention of stroke and systemic embolism in patients with NVAF, patients should receive the lower dose of apixaban 2.5 mg twice daily.
Danish: - til forebyggelse af apopleksi og systemisk emboli hos patienter med NVAF, skal patienten have den lave apixabandosis på 2,5 mg to gange dagligt.
English: Recurrent VTE or VTErelated death
Danish: VTE eller VTErelateret død
English: The dosing regimen should be reduced to a 5 mg loading dose followed by 2.5 mg twice daily if the patient meets the criteria for dose reduction (see above sections Dose reduction and Renal impairment).
Danish: Dosisregimet skal reduceres til en støddosis på 5 mg efterfulgt af 2,5 mg to gange dagligt, hvis patienten opfylder kriterierne for dosisreduktion (se Dosisreduktion og Nedsat nyrefunktion ovenfor).
English: Haemodialysis decreased apixaban AUC by 14% in subjects with end-stage renal disease (ESRD), when a single dose of apixaban 5 mg was administered orally.
Danish: Hæmodialyse reducerede apixabans AUC med 14% hos forsøgspersoner med terminal nyresygdom (ESRD), når 5 mg apixaban som enkeltdosis blev administreret oralt.
English: The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers (e.g., phenytoin, carbamazepine,
Danish: Samtidig brug af apixaban og andre kraftige CYP3A4- og P-gp-induktorer (f.eks. phenytoin, carbamazepin,
English: - Unit dose blisters in cartons of 60 x 1 and 100 x 1 film-coated tablets for delivery in hospitals are also available.
Danish: - Enkeltdosis-blisterpakninger i æsker med 60 x 1 og 100 x 1 filmovertrukne tabletter til hospitalsbrug kan også fås.
English: In subjects with end-stage renal disease (ESRD), the AUC of apixaban was increased by 36% when a single dose of apixaban 5 mg was administered immediately after haemodialysis, compared to that seen in subjects with normal renal function.
Danish: Hos forsøgspersoner med terminal nyresygdom (ESRD) blev apixabans AUC øget med 36%, når 5 mg apixaban som enkeltdosis blev administreret umiddelbart efter hæmodialyse, sammenlignet med AUC hos forsøgspersoner med normal nyrefunktion.
English: Bristol-Myers Squibb S.r.l Loc. Fontana del Ceraso 03012 Anagni (FR) Italy
Danish: Loc. Fontana del Ceraso 03012 Anagni (FR) Italien
English: Haemorrhage risk
Danish: Blødningsrisiko
English: Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325 mg once a day.
Danish: Der blev ikke observeret klinisk signifikante farmakokinetiske eller farmakodynamiske interaktioner ved samtidig indtagelse af apixaban og 325 mg ASA 1 gang dagligt.
English: Following surgery, other platelet aggregation inhibitors are not recommended concomitantly with Eliquis (see section 4.5).
Danish: Efter kirurgi frarådes anvendelse af trombocytaggregationshæmmere sammen med Eliquis (se pkt.
English: Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 5).
Danish: Der blev også opnået statistisk signifikant fordel på de sekundære endepunkter for både major blødning og død uanset årsag (se Tabel 5).
English: For patients undergoing catheter ablation for atrial fibrillation, Eliquis treatment does not need to be interrupted (see sections 4.2, 4.3 and 4.5).
Danish: For patienter, der får foretaget kateterablation for atrieflimren, er det ikke nødvendigt at seponere behandlingen med Eliquis (se pkt.
English: Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 7).
Danish: Der blev opnået statistisk signifikant overlegenhed på de sekundære endepunkter for både major blødning og død uanset årsag (se Tabel 7).
English: Yellow, round tablets debossed with 893 on one side and 2½ on the other side.
Danish: Gule, runde tabletter præget med 893 på den ene side, og 2½ på den anden side.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Danish: DATO FOR ÆNDRING AF TEKSTEN Yderligere information om Eliquis findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu
English: - Unit dose blisters in cartons of 100 x 1 film-coated tablets for delivery in hospitals are also available.
Danish: - Enkeltdosis-blisterpakninger i æsker med 100 x 1 filmovertrukne tabletter til hospitalsbrug kan også fås.